HSP90AB1 and Kaposi's sarcoma: These experiments support the notion that LANA, AKT and ephrinB2 are bona fide targets of Hsp90 in KS tumors in vivo and provide proof-of-principle for the use of Hsp90 inhibitors as potential anti-KS therapeutics.